Literature DB >> 19630736

Ethanol withdrawal and hyperalgesia.

Michael B Gatch1.   

Abstract

Hyperalgesia has been observed during ethanol withdrawal, comparable to the hyperalgesia observed during withdrawal from opioids. To determine the extent of this phenomenon and its potential mechanisms, both behavioral and in vitro studies are examined, and the roles of GABA(A), glutamate and other receptors in mediating the acute and chronic antinociceptive effects of ethanol are reviewed. Hyperalgesia during ethanol withdrawal is a robust phenomenon that has been observed in various strains of mice and rats, with different methods of exposure to ethanol, and with a variety of nociceptive assays. GABA receptors play an important role in mediating the antinociceptive effects of ethanol, but too little research has examined the role of glutamate receptors to make any conclusion about their importance. Adenosine receptors, calcium channels, and protein kinase C appear to play central roles in mediating tolerance to antinociceptive effects of ethanol and mediating the hyperalgesia seen during withdrawal. Although some key pathways have been identified, further mechanistic work is necessary to fully characterize the mechanisms for the development of hyperalgesia following chronic exposure to ethanol. An understanding of how the hyperalgesia may fit in with other manifestations of ethanol withdrawal may be an important variable in determining treatment outcome. Clinical research is essential to determine the significance of the hyperalgesia to the severity of withdrawal and to relapse.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19630736     DOI: 10.2174/1874473710902010041

Source DB:  PubMed          Journal:  Curr Drug Abuse Rev        ISSN: 1874-4737


  25 in total

Review 1.  Interrelations between pain and alcohol: An integrative review.

Authors:  Emily L Zale; Stephen A Maisto; Joseph W Ditre
Journal:  Clin Psychol Rev       Date:  2015-02-25

Review 2.  Drug Addiction: Hyperkatifeia/Negative Reinforcement as a Framework for Medications Development.

Authors:  George F Koob
Journal:  Pharmacol Rev       Date:  2021-01       Impact factor: 25.468

Review 3.  Alcohol dependence as a chronic pain disorder.

Authors:  Mark Egli; George F Koob; Scott Edwards
Journal:  Neurosci Biobehav Rev       Date:  2012-09-11       Impact factor: 8.989

4.  An alcohol withdrawal test battery measuring multiple behavioral symptoms in mice.

Authors:  Pamela Metten; Jason P Schlumbohm; Lawrence C Huang; Gian D Greenberg; Wyatt R Hack; Stephanie E Spence; John C Crabbe
Journal:  Alcohol       Date:  2017-09-06       Impact factor: 2.405

5.  Acute ethanol withdrawal impairs contextual learning and enhances cued learning.

Authors:  Megan E Tipps; Jonathan D Raybuck; Kari J Buck; K Matthew Lattal
Journal:  Alcohol Clin Exp Res       Date:  2015-02       Impact factor: 3.455

6.  Increased alcohol consumption in urocortin 3 knockout mice is unaffected by chronic inflammatory pain.

Authors:  Monique L Smith; Ju Li; Andrey E Ryabinin
Journal:  Alcohol Alcohol       Date:  2014-12-01       Impact factor: 2.826

7.  Acupuncture for alcohol use disorder.

Authors:  Pei Chen; Jing Li; Xiao Han; Dennis Grech; Ming Xiong; Alex Bekker; Jiang-Hong Ye
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2018-03-10

8.  Reductions in physical pain predict lower risk of relapse following alcohol treatment.

Authors:  A Jakubczyk; M A Ilgen; M Kopera; A Krasowska; A Klimkiewicz; A Bohnert; F C Blow; K J Brower; M Wojnar
Journal:  Drug Alcohol Depend       Date:  2015-11-23       Impact factor: 4.492

9.  Alcohol effects on synaptic transmission in periaqueductal gray dopamine neurons.

Authors:  Chia Li; Nora M McCall; Alberto J Lopez; Thomas L Kash
Journal:  Alcohol       Date:  2013-04-15       Impact factor: 2.405

10.  High mobility group box 1/Toll-like receptor danger signaling increases brain neuroimmune activation in alcohol dependence.

Authors:  Fulton T Crews; Liya Qin; Donna Sheedy; Ryan P Vetreno; Jian Zou
Journal:  Biol Psychiatry       Date:  2012-12-01       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.